SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Scancell Reports Modi-1 Immune Responses Linked to Longer Progression-Free Survival

Scancell said immune responses to its Modi-1 therapy were linked to longer progression-free survival in a Phase 2 kidney cancer trial.

Related stories